Empagliflozin: Discovery, Development, Safety and Pharmacovigilance

Boehringer Ingelheim's empagliflozin development, major trials, approvals, serious risks, vulnerable populations and practical benefit–risk surveillance.

Take test

Empagliflozin: Discovery, Development, Safety and Pharmacovigilance

Empagliflozin, an oral sodium–glucose cotransporter 2 (SGLT2) inhibitor, illustrates an unusual medicine lifecycle: a glucose-lowering mechanism first studied in type 2 diabetes subsequently produced cardiovascular, heart-failure and kidney outcome evidence supporting treatment of many patients without diabetes. These changing populations alter both the drug's benefit–risk balance and what pharmacovigilance systems must look for [1–6].

1. Identity and scientific rationale

The canonical active-substance name is empagliflozin. Jardiance is a familiar single-substance brand; fixed-dose combinations have additional active ingredients and different product-specific considerations. Do not allocate combination-specific adverse events, prescribing totals or revenues automatically to the empagliflozin constituent.

Most filtered glucose is recovered by transporters in the proximal renal tubule, with SGLT2 responsible for a large fraction of reabsorption. By inhibiting SGLT2, empagliflozin promotes urinary glucose excretion without directly increasing insulin secretion. Glucose lowering is therefore insulin-independent, but the accompanying glycosuria and osmotic diuresis can increase susceptibility to genital fungal infection and fluid depletion. The renal mechanism also explains why its glucose-lowering performance diminishes at lower eGFR, even though trials have demonstrated kidney and cardiac benefits in selected patients with CKD [1,2,6].

Development within Boehringer Ingelheim's SGLT2 medicinal-chemistry programme led to the candidate identified in early investigations as BI 10773. Early phase clinical studies addressed pharmacokinetics, dose-related urinary glucose excretion and tolerability before larger studies of glycaemic efficacy. Mechanistic explanations for later cardiorenal benefit include effects on renal haemodynamics and sodium handling, but proposed downstream pathways are not equivalent to individually proven causal mechanisms of clinical benefit.

2. Development and partnership history

Empagliflozin originated in Boehringer Ingelheim's research programme. Boehringer Ingelheim and Eli Lilly announced a global diabetes alliance on 11 January 2011 [8], which subsequently provided an important development and commercialisation context for empagliflozin and other diabetes therapies. Alliance-level financial figures should not be portrayed as empagliflozin-only sales. The EMA names Boehringer Ingelheim International GmbH as the EU marketing-authorisation holder [1].

EU authorisation for Jardiance was granted 22 May 2014, and the FDA label records initial US approval in 2014. Authorisation then evolved as evidence accumulated. The current EMA overview identifies treatment of insufficiently controlled type 2 diabetes in adults and children aged 10 years or older, symptomatic chronic heart failure in adults, and chronic kidney disease in adults [1]. The US label additionally frames specific diabetes/CVD and CKD outcome indications and limitations [2]. Claims about indications must identify region, date and clinical population.

3. From glycaemic endpoints to clinical outcomes

Early diabetes trials evaluated changes in HbA1c and glucose alongside treatment tolerability. These are useful metabolic endpoints but cannot by themselves establish reduced cardiovascular mortality, heart-failure hospitalisation or kidney failure. Large, purpose-designed outcome trials subsequently established those endpoints in particular populations.

EMPA-REG OUTCOME randomised patients with type 2 diabetes and established cardiovascular disease to empagliflozin or placebo alongside usual treatment. It reported beneficial cardiovascular outcomes, including a reduction in cardiovascular death, and helped redirect research beyond glycaemic control [3]. This was not a primary-prevention study of all people with diabetes; the population restriction matters when interpreting the results.

The distinction between surrogate and clinical endpoints is central for pharmacovigilance. A medicine can have diminished HbA1c effects in severe renal impairment while still improving long-term kidney outcomes in an appropriately studied CKD population. Equally, improvement in a composite outcome does not establish a significant improvement in each component.

4. Heart-failure evidence across ejection fraction

EMPEROR-Reduced included 3,730 patients with symptomatic heart failure and ejection fraction at most 40%. Cardiovascular death or hospitalisation for heart failure occurred in 19.4% receiving empagliflozin versus 24.7% receiving placebo over median 16 months (hazard ratio 0.75; 95% CI 0.65–0.86) [4]. The endpoint is a composite: do not state that its relative risk reduction was separately demonstrated for cardiovascular death.

EMPEROR-Preserved included 5,988 patients with heart failure and ejection fraction greater than 40%; it demonstrated benefit on the combined endpoint of cardiovascular death or hospitalisation for heart failure, chiefly through fewer hospitalisations [5]. These trials extended the scientific case for SGLT2 inhibition into heart failure independently of diabetes status. Their specific entry criteria and background treatment remain relevant when evaluating results in older, frail or multimorbid patients.

5. Chronic kidney disease: EMPA-KIDNEY

EMPA-KIDNEY randomised 6,609 people with CKD, more than half without diabetes. Over a median two years, kidney disease progression or cardiovascular death occurred in 432/3,304 (13.1%) with empagliflozin and 558/3,305 (16.9%) with placebo: hazard ratio 0.72 (95% CI 0.64–0.82) [6]. The trial did not establish statistically significant differences for each component of every secondary composite outcome, including hospitalisation for heart failure or cardiovascular death considered as a separate composite [6].

A later follow-up reported persistence of some benefits beyond the active trial period [7]. That follow-up was not a new period of blinded randomised drug exposure; open-label SGLT2 inhibitor use could occur. Treat it as supporting longer-term evidence within its methodological limits.

Development evidence Studied population Main contribution Caution in interpretation
Early diabetes trials Type 2 diabetes Glycaemic efficacy, tolerability HbA1c is not a clinical outcomes proxy
EMPA-REG OUTCOME Diabetes with established CVD Cardiovascular outcome evidence Not a universal diabetes population
EMPEROR-Reduced Symptomatic HF, LVEF ≤40% HF/CV composite benefit Components are not equivalent
EMPEROR-Preserved Symptomatic HF, LVEF >40% Benefit across broader HF phenotypes Mainly driven by HF hospitalisation
EMPA-KIDNEY CKD with/without diabetes Kidney progression/CV-death reduction Observe exclusions and secondary endpoint precision

The trials cannot be directly ranked against each other because patients, concomitant care and endpoints differed [3–6].

6. Regulatory indication and renal-function distinctions

The EU Jardiance product information was last updated 24 March 2026 at the time of review [1]. US Jardiance prescribing information revised October 2025 identifies distinct indications for diabetes control, cardiovascular risk reduction in people with diabetes and established cardiovascular disease, heart failure, and CKD [2]. The jurisdiction-specific label, not class assumptions, must control the final prescribing interpretation.

In the United States, empagliflozin is not recommended solely to improve glycaemic control in type 2 diabetes when eGFR is below 30 mL/min/1.73 m². That limitation should not be misquoted as a blanket prohibition across all approved cardiorenal indications. US CKD information separately identifies populations in which treatment is not expected to be effective, including polycystic kidney disease and certain intensive immunosuppression situations [2]. A patient may therefore have a current indication even when the glucose-lowering effect is small.

7. Serious and clinically important safety concerns

Ketoacidosis and misleading blood glucose

SGLT2 inhibitors can contribute to diabetic ketoacidosis and other ketoacidosis presentations, sometimes without conspicuous hyperglycaemia. Prolonged fasting, surgery, acute illness, dehydration, reduced carbohydrate intake and changes in insulin treatment warrant particular attention. When symptoms or metabolic findings suggest ketoacidosis, check ketones and acid–base status rather than using a near-normal blood glucose measurement to rule it out. Treatment should be interrupted and ketoacidosis managed urgently if suspected [1,2].

The US label recommends withholding Jardiance at least three days before surgery or procedures associated with prolonged fasting, if possible [2]. This precise statement is tied to US product information; check the current local European SmPC for EU interruption recommendations. The decision to restart requires assessment of clinical recovery and the precipitating factors.

Volume depletion, hypotension and acute renal events

Glycosuria and osmotic diuresis can contribute to volume loss and hypotension. Risk assessment should address baseline renal function, age, concurrent diuretics, blood pressure, oral intake and intercurrent illness. A modest early change in eGFR associated with haemodynamic effects is not necessarily structural acute kidney injury; conversely, serious creatinine elevation, oliguria or shock require assessment for dehydration, infection, decompensated heart failure and other causes [1,2].

The long-term renoprotective results of EMPA-KIDNEY do not preclude an acute illness-associated renal event in an individual patient. A coherent case report should include baseline and sequential kidney measurements, fluid balance and concomitant medicines.

Genital mycotic infection and serious genitourinary disease

Increased urinary glucose creates a plausible environment for genital fungal infection. Labels additionally warn about serious urinary tract infections, including pyelonephritis and urosepsis, and rare necrotising fasciitis of the perineum (Fournier gangrene). In a patient with painful genital or perineal swelling, erythema, systemic symptoms or rapid deterioration, urgent clinical evaluation and appropriate medical/surgical treatment take priority over administrative case processing [2].

An analyst must distinguish minor recurrent candidiasis from severe tissue infection. Document site, diagnosis, cultures when available, imaging, surgery, diabetes status, immunosuppression and other predisposing factors. Serious cases may need expedited pharmacovigilance handling under the applicable reporting framework, independently of the emergency treatment already indicated.

Hypoglycaemia, lower-limb events and hypersensitivity

The mechanism does not generally drive insulin secretion, so hypoglycaemia is especially relevant with insulin or insulin secretagogues. The FDA label separately describes increased hypoglycaemia risk among paediatric recipients regardless of insulin use [2]. Assessment should identify co-medications, meals, glucose evidence, renal status and prescribing changes.

US information includes a lower-limb amputation warning and recommends monitoring for foot ulcers and infections [2]. This must not be transformed into an unsupported claim about a precise empagliflozin-specific excess risk. Severe hypersensitivity is also labelled. Maintain separation between precautionary warnings, observed adverse reactions, established causality and unresolved signals.

8. Special populations and combination medicines

Pregnancy and lactation

The US label advises against empagliflozin particularly during the second and third trimesters, drawing on concerns about renal development; breastfeeding during treatment is not recommended [2]. Pregnancy reports should capture gestational age at first and last exposure, diabetes severity, renal disease, background medicines, prenatal results and infant outcome. Do not infer teratogenic causation solely from a coincident adverse pregnancy outcome. Check the European wording independently rather than equating regional labels.

Paediatrics

The EU diabetes indication extends to children 10 years and older, not to paediatric HF or CKD automatically [1]. An adverse-event report should record age, growth/development stage, diabetes phenotype, intercurrent illness and insulin background. Adults and children may differ in the importance of hypoglycaemia and dehydration monitoring.

Pharmacodynamic interactions and fixed combinations

Loop diuretics can increase vulnerability to volume depletion, and insulin or sulfonylureas can change hypoglycaemia risk. These are often pharmacodynamic interactions rather than proof of a CYP-mediated metabolic interaction. A fixed-dose combination with metformin, for example, also creates metformin-specific contraindications and adverse-event considerations. Record the actual formulation and every active ingredient; never attribute a complete combination's risk profile to empagliflozin alone.

9. Regulatory surveillance as the treated population expands

For a long-standing diabetes medicine now used in HF and CKD, background rates of kidney dysfunction, fluid overload, urinary infection, hospitalisation and death vary substantially by indication. Apparent increases in spontaneous reports can arise from increased exposure, indication expansion, stimulated reporting or changes in case ascertainment; reporting-rate comparisons without valid denominators cannot establish incidence or causal excess.

Evidence synthesis should combine well-documented individual cases, controlled trial outcomes, active surveillance and appropriately designed observational studies. In assessing a possible new signal, ask whether the apparent event is medically coherent, temporally plausible, different from expected disease progression, or concentrated in a vulnerable subgroup. Comparisons to other SGLT2 inhibitors inform class context but cannot replace empagliflozin-specific evidence.

10. Practical case assessment

At intake identify the exact product, indication, patient, event and sequence. Confirm region and product information version. For heart-failure and CKD treatment, do not assume diabetes; for diabetic ketoacidosis, do not assume severe hyperglycaemia.

Suspected event Essential follow-up Important confounders
Ketoacidosis Ketones, pH, bicarbonate, blood glucose, onset, food intake, infection, insulin changes Insulin deficiency, starvation, sepsis, alcohol
Acute kidney injury/hypotension Serial creatinine/eGFR, blood pressure, fluid loss, diuretic and RAAS-agent doses Dehydration, HF progression, obstruction, sepsis
Genital infection or urosepsis Clinical site, severity, culture, imaging, treatment, onset Diabetes, catheter, structural urinary disease
Fournier gangrene Surgical/clinical confirmation, progression, site, microbiology, outcomes Diabetes, obesity, immunosuppression
Hypoglycaemia Glucose readings, insulin and secretagogue doses, meals, renal status Missed meals, insulin error, reduced clearance
Pregnancy exposure Exposure dates, gestation, maternal condition, co-medications, fetal/infant follow-up Background obstetric risk and other treatments

These are recommended follow-up data, not a replacement for the minimum criteria that determine an ICSR's validity under applicable regulations. Seriousness, expectedness/listedness, causality and reportability are distinct assessments.

Illustrative scenario: diarrhoeal illness in a patient with CKD

A person with CKD and heart failure taking empagliflozin and a loop diuretic develops gastroenteritis, hypotension and increased serum creatinine. Temporal association alone is insufficient. Investigate fluid intake and losses, timing of both medicines, blood pressure, baseline renal function, infection and kidney function after treatment adjustment. Document plausible multiple contributors and report according to applicable obligations. This is a teaching example, not a real case or confirmed causal attribution.

Illustrative scenario: acidosis without high glucose

A person with type 2 diabetes continues empagliflozin during prolonged fasting and is admitted with nausea, rapid breathing, elevated ketones and metabolic acidosis, but only modest blood-glucose elevation. The key is to recognise a potential ketoacidosis syndrome promptly; evaluate concomitant insulin changes, illness and other causes, and record laboratory confirmation and treatment course. Do not equate therapeutic class plausibility with certainty about the individual's cause.

11. Operational pharmacovigilance and QPPV oversight

A medically useful safety system should trace intake and follow-up, relevant MedDRA coding, case duplicates, clinical review, decisions on seriousness and expectedness, submission obligations and follow-up requests. For signal management, examine exposure by indication, country and formulation as well as the quality and completeness of reported events.

The QPPV should be able to explain how serious safety information flows from medical information teams, patient programmes, partners and literature into case processing, signal review, regulatory evaluation and, where justified, updates to reference safety information or the risk-management plan. The evidence chain matters more than a dashboard metric in isolation. Suggested monitoring is a quality-system practice, not an invented legal deadline.

12. Uncertainty and future evaluation

Trials establish meaningful cardiorenal benefits, but very frail patients, multiple concurrent diuretics, acute illness and highly complex comorbidity may be incompletely represented. Surveillance questions include severe ketoacidosis in atypical contexts, effectiveness of treatment-interruption counselling and the clinical characterization of serious genitourinary events. A descriptive signal does not establish risk magnitude; pharmacoepidemiological studies need appropriate comparators, confounder control and suitable follow-up windows.

Key Takeaways

Empagliflozin's safety assessment must follow the indication and the patient rather than an outdated assumption that it is solely a diabetes medicine. Large controlled trials support benefits in cardiovascular disease, heart failure and CKD, while label-defined safety risks require attention to acute illness, fasting, ketoacidosis, infection and hypovolaemia. Different indications and renal thresholds must not be conflated. Reliable pharmacovigilance depends on confirmed clinical phenotypes, exposure history, comorbidity, combination components and up-to-date jurisdiction-specific product information.

References

  1. European Medicines Agency. Jardiance: EPAR and EU product information. Authorised 22 May 2014; product information updated 24 March 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance
  2. US FDA. Jardiance (empagliflozin) prescribing information. Revised October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204629s063lbl.pdf
  3. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
  4. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413–1424. https://doi.org/10.1056/NEJMoa2022190
  5. Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451–1461. https://doi.org/10.1056/NEJMoa2107038
  6. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117–127. https://doi.org/10.1056/NEJMoa2204233
  7. EMPA-KIDNEY Collaborative Group. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2409183

  8. Eli Lilly and Company / Boehringer Ingelheim. Strategic alliance to bring new diabetes treatments to patients worldwide. Corporate announcement, 11 January 2011. https://investor.lilly.com/node/21776

Regulatory Note

Prepared from regulatory and primary scientific information examined 22 October 2026. This is professional education, not an individual prescribing instruction. Product information and regulatory requirements change and may differ between EU and US jurisdictions. Verify the current authorised indication, local SmPC or prescribing information, patient-specific contraindications and relevant guidance before clinical or regulatory action.

Revision History

Last reviewed: 2026-10-22

QPPV.com